Patterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study

Basit Öğe Kaydı
dc.contributor.authorBuyukasik, Yahya
dc.contributor.authorAli, Ridvan
dc.contributor.authorTurgut, Mehmet
dc.contributor.authorSaydam, Guray
dc.contributor.authorYavuz, Selim
dc.contributor.authorUnal, Ali
dc.contributor.authorAr, Muhlis Cem
dc.date.accessioned2024-04-24T17:24:28Z
dc.date.available2024-04-24T17:24:28Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: This study aimed to evaluate real-life data on patterns of hydroxyurea prescription/use in polycythemia vera (PV). Materials and Methods: This retrospective chart review study included PV patients who had received hydroxyurea therapy for at least 2 months after PV diagnosis. Data were collected from 10 representative academic medical centers. Results: Of 657 patients, 50.9% were in the high-risk group (age 60 years and/or history of thromboembolic event). The median duration of hydroxyurea therapy was 43.40 months for all patients; 70.2% of the patients had ongoing hydroxyurea therapy at last followup. Hydroxyurea was discontinued in 22.4% of the patients; the most common reason was death (38.5%). The predicted time until hydroxyurea discontinuation was 187.8 months (standard error: +/- 21.7) for all patients. This duration was shorter in females (140.3 +/- 37.7 vs. 187.8 +/- 29.7) (p=0.08). This trend was also observed in surviving patients aged >= 50 years at hydroxyurea initiation (122.2 +/- 12.4 vs. 187.8 +/- 30.7, p=0.03). Among the patients who were still on hydroxyurea therapy, 40.3% had a hematocrit concentration of >= 45% at their last followup visit, and the rate of patients with at least one elevated blood cell count was 67.8%. Conclusion: Hydroxyurea prescription patterns and treatment aims are frequently not in accordance with the guideline recommendations. Its discontinuation rate is higher in females.en_US
dc.identifier.doi10.4274/tjh.galenos.2020.2019.0431
dc.identifier.endpage185en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue3en_US
dc.identifier.pmid32075363
dc.identifier.scopus2-s2.0-85090076483
dc.identifier.scopusqualityQ3
dc.identifier.startpage177en_US
dc.identifier.trdizinid380853
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2020.2019.0431
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/380853
dc.identifier.urihttps://hdl.handle.net/11468/19691
dc.identifier.volume37en_US
dc.identifier.wosWOS:000564138800005
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal of Hematology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPolycythemia Veraen_US
dc.subjectHydroxyureaen_US
dc.subjectTreatment Outcomeen_US
dc.titlePatterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Studyen_US
dc.titlePatterns of Hydroxyurea Prescription and Use in Routine Clinical Management of Polycythemia Vera: A Multicenter Chart Review Study
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu